SEC Comment Letter for Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — Sep 14, 2022
Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: Sept. 14, 2022 · CIK: 0000715446 · Accession: 0000000000-22-010047
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267369
Letter
United States securities and exchange commission logo September 14, 2022 Amit Kumar Chief Executive Officer Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 Re:Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 9, 2022 File No. 333-267369 Dear Dr. Kumar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew Bernstein, Esq.
Show Raw Text
United States securities and exchange commission logo
September 14, 2022
Amit Kumar
Chief Executive Officer
Anixa Biosciences, Inc.
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
Re:Anixa Biosciences, Inc.
Registration Statement on Form S-3
Filed September 9, 2022
File No. 333-267369
Dear Dr. Kumar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew Bernstein, Esq.